The abstract is read at the publisher; the summary is JClub's.
An LLM-driven network medicine framework for ER+ breast cancer identifies 166 significant drug pairs at FDR ≤ 0.05, including 31 with ClinicalTrials.gov precedent.
- Why it matters: Drug repurposing can speed ER+ therapy discovery, but selecting effective combinations is hard without integrating literature evidence with pathway context.
- What they did: The approach mined drug–target links from 595,122 PubMed abstracts, built a cross-model consensus network, overlaid it on the KEGG estrogen signaling pathway, and ranked pairs using ComboRank with RAG validation and agreement metrics.
- The result: It reports 166 significant pairs at FDR ≤ 0.05, including 31 with clinical-trial precedent, plus 11 exact pairs additionally supported by the pathway overlay.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.